Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)
Conclusion Sunitinib was tolerable as maintenance therapy but median PFS was significantly lower than the predefined threshold of 6 months.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Docetaxel | Drugs & Pharmacology | Investigational New Drugs | Oral Cancer | Prostate Cancer | Study | Taxotere | Toxicology